XML 52 R39.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Commitment and Contingencies - Collaboration Agreements (Details) - USD ($) | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Apr. 30, 2021 | Mar. 31, 2020 | Sep. 30, 2022 | Jun. 30, 2021 | Aug. 31, 2021
Series A Preferred Stock |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement (in shares) |  |  |  | 418,559 |
Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement |  |  |  | $ 2,837,832 |
Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Maximum obligation amount |  | $ 800,000 |  |  |
Number of securities called by warrants (in shares) |  |  |  |  | 111,576
Warrant exercise price (in dollars per share) |  |  |  |  | $ 7.17
Quarterly sales payment due upon completion, percentage |  | 1.00% |  |  |
Quarterly sales payment due upon completion, period of payment |  | 15 years |  |  |
Integral | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Maximum obligation amount | $ 300,000 |  |  |  |
Maximum development and regulatory milestone payments |  |  | $ 55,000,000 |  |
Maximum sales milestone payments | $ 130,000,000 |  |  |  |
Tiered royalty payment, percent (up to) | 12.00% |  |  |  |
Research and development costs incurred |  |  | $ 500,000 |  |
Integral | Series A Preferred Stock | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement (in shares) | 418,559 |  |  |  |
Fair value of Series A preferred stock issued in conjunction with collaboration and licensing agreement | $ 2,800,000 |  |  |  |
Scale-up, 100 kilograms of GMP-grade compound | Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Milestone payment |  | $ 2,000,000 |  |  |
Scale-up, 300 kilograms of GMP-grade compound | Tyligand | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Milestone payment |  | $ 3,000,000 |  |  |

X
- Definition Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum + References No definition available. + Details
Name: | cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum
Namespace Prefix: | cntx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights and Obligations, Milestone Payment + References No definition available. + Details
Name: | cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment
Namespace Prefix: | cntx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent + References No definition available. + Details
Name: | cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent
Namespace Prefix: | cntx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum + References No definition available. + Details
Name: | cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
Namespace Prefix: | cntx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period + References No definition available. + Details
Name: | cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod
Namespace Prefix: | cntx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent + References No definition available. + Details
Name: | cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
Namespace Prefix: | cntx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights and Obligations, Upfront Payment + References No definition available. + Details
Name: | cntx_CollaborativeArrangementRightsAndObligationsUpfrontPayment
Namespace Prefix: | cntx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Temporary Equity, Stock Issued During Period, Shares, Issued For Services + References No definition available. + Details
Name: | cntx_TemporaryEquityStockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | cntx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Temporary Equity, Stock Issued During Period, Value, Issued For Services + References No definition available. + Details
Name: | cntx_TemporaryEquityStockIssuedDuringPeriodValueIssuedForServices
Namespace Prefix: | cntx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |